{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:14:14Z","timestamp":1774484054145,"version":"3.50.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Allogeneic stem cell transplantation is used to cure hematologic malignancies or deficiencies of the hematopoietic system. It is associated with severe immunodeficiency of the host early after transplant and therefore early reactivation of latent herpesviruses such as CMV and EBV within the first 100 days are frequent. Small studies and case series indicated that application of herpes virus specific T cells can control and prevent disease in this patient population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We report the results of a randomized controlled multi centre phase I\/IIa study (MULTIVIR-01) using a newly developed T cell product with specificity for CMV and EBV derived from the allogeneic stem cell grafts used for transplantation. The study aimed at prevention and preemptive treatment of both viruses in patients after allogeneic stem cell transplantation targeting first infusion on day +30. Primary endpoints were acute transfusion reaction and acute-graft versus-host-disease after infusion of activated T cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty-three patients were screened and 9 patients were treated with a total of 25 doses of the T cell product. We show that central manufacturing can be achieved successfully under study conditions and the product can be applied without major side effects. Overall survival, transplant related mortality, cumulative incidence of graft versus host disease and number of severe adverse events were not different between treatment and control groups. Expansion of CMV\/EBV specific T cells was observed in a fraction of patients, but overall there was no difference in virus reactivation.  <\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our study results indicate peptide stimulated epitope specific T cells derived from stem cell grafts can be administered safely for prevention and preemptive treatment of reactivation without evidence for induction of acute graft versus host disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:uri>https:\/\/clinicaltrials.gov<\/jats:uri>, identifier NCT02227641.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1251593","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:45:58Z","timestamp":1698641158000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Prevention of CMV\/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I\/IIa MULTIVIR-01 study"],"prefix":"10.3389","volume":"14","author":[{"given":"Armin","family":"Gerbitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Gary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Moosmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Hirschbuehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Hauptrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Teschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf","family":"Roesler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Spriewald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Tischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Moi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Balzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Schaffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Bausenwein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Brestrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Maas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Herold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Strobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Weisbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo","family":"Hansmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda","family":"Lammoglia-Cobo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"Remberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Mackensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010163","article-title":"Optimizing antiviral dosing for HSV and CMV treatment in immunocompromised patients","volume":"15","author":"Huntjens","year":"2023","journal-title":"Pharmaceutics"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18763","article-title":"Post-transplant lymphoproliferative disorder: Update on treatment and novel therapies","volume":"201","author":"Atallah-Yunes","year":"2023","journal-title":"Br J Haematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161846","article-title":"Human immunity against EBV-lessons from the clinic","volume":"214","author":"Tangye","year":"2017","journal-title":"J Exp Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2023.102305","article-title":"alphabeta and gammadelta T-cell responses to Epstein-Barr Virus: insights in immunocompetence, immune failure and therapeutic augmentation in transplant patients","volume":"82","author":"Eiz-Vesper","year":"2023","journal-title":"Curr Opin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","article-title":"Cellular responses to viral infection in humans: lessons from Epstein-Barr virus","volume":"25","author":"Hislop","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236356","article-title":"Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells","volume":"115","author":"Moosmann","year":"2010","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1099-1654(199709)7:3<181::aid-rmv200>3.0.co;2-w","article-title":"T cell therapy of human CMV and EBV infection in immunocompromised hosts","volume":"7","author":"Riddell","year":"1997","journal-title":"Rev Med Virol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902233","article-title":"CMV-specific TCR-transgenic T cells for immunotherapy","volume":"183","author":"Schub","year":"2009","journal-title":"J Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26708","article-title":"Efficacy of pp65-specific TCR-T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation","volume":"97","author":"Liu","year":"2022","journal-title":"Am J Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third party virus-specific T-cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/v14112370","article-title":"Adoptive immunotherapy for prophylaxis and treatment of cytomegalovirus infection","volume":"14","author":"Ouellette","year":"2022","journal-title":"Viruses"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165476","article-title":"Third party CMV viral specific T-cells for refractory CMV viremia and disease after hematopoietic transplant","volume":"133","author":"Prockop","year":"2023","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.12.787","article-title":"Reprint of: virus-specific T cells: broadening applicability","volume":"24","author":"Barrett","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol therapy: J Am Soc Gene Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007103","article-title":"Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant","volume":"6","author":"Jiang","year":"2022","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003283","article-title":"Off-the-shelf EBV-specific T-cell immunotherapy for EBV-associated PTLD","volume":"104","author":"O\u2019Reilly","year":"2020","journal-title":"Transplantation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1010206","DOI":"10.1371\/journal.ppat.1010206","article-title":"Reconstitution of EBV-directed T cell immunity by adoptive transfer of peptide-stimulated T cells in a patient after allogeneic stem cell transplantation for AITL","volume":"18","author":"Lammoglia Cobo","year":"2022","journal-title":"PloS pathogens."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.111","article-title":"T-cell therapy in the treatment of post-transplant lymphoproliferative disease","volume":"9","author":"Bollard","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12967-018-1498-3","article-title":"Clinical-grade generation of peptide-stimulated CMV\/EBV-specific T cells from G-CSF mobilized stem cell grafts","volume":"16","author":"Gary","year":"2018","journal-title":"J Trans Med"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.77.9.5226-5240.2003","article-title":"Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers","volume":"77","author":"Elkington","year":"2003","journal-title":"J Virol"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1007\/s002510000271","article-title":"Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes","volume":"52","author":"Longmate","year":"2001","journal-title":"Immunogenetics"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V90.5.1751","article-title":"Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection","volume":"90","author":"Diamond","year":"1997","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1086\/339963","article-title":"Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype","volume":"185","author":"Khan","year":"2002","journal-title":"J Infect Dis"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.73.3.2099-2108.1999","article-title":"The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo","volume":"73","author":"Weekes","year":"1999","journal-title":"J Virol"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.151.8.3971","article-title":"Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes","volume":"151","author":"Gavin","year":"1993","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e1003383","DOI":"10.1371\/journal.ppat.1003383","article-title":"Presentation of an immunodominant immediate-early CD8+ T cell epitope resists human cytomegalovirus immunoevasion","volume":"9","author":"Ameres","year":"2013","journal-title":"PloS pathogens."},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.67.12.7428-7435.1993","article-title":"HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2","volume":"67","author":"Lee","year":"1993","journal-title":"J Virol"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1084\/jem.185.9.1605","article-title":"Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response","volume":"185","author":"Steven","year":"1997","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200009)30:9<2531::AID-IMMU2531>3.0.CO;2-O","article-title":"A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening","volume":"30","author":"Saulquin","year":"2000","journal-title":"Eur J Immunol"},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.10309","article-title":"Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2","volume":"99","author":"Meij","year":"2002","journal-title":"Int J Cancer"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1084\/jem.181.6.2221","article-title":"Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised","volume":"181","author":"Hill","year":"1995","journal-title":"J Exp Med"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1099\/0022-1317-75-9-2489","article-title":"Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3","volume":"75","author":"Burrows","year":"1994","journal-title":"J Gen Virol"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.69.8.4872-4879.1995","article-title":"Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus","volume":"69","author":"Bogedain","year":"1995","journal-title":"J Virol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.15.1.405","article-title":"Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection","volume":"15","author":"Rickinson","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02940.x","article-title":"Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation","volume":"51","author":"Schmitt","year":"2011","journal-title":"Transfusion"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.015","article-title":"Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia","volume":"21","author":"Koehne","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2415","article-title":"Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting","volume":"29","author":"Pfeiffer","year":"2023","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2016.1221022","article-title":"CMV-specific immune reconstitution following allogeneic stem cell transplantation","volume":"7","author":"Blyth","year":"2016","journal-title":"Virulence"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20042384","article-title":"Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells","volume":"201","author":"Bunde","year":"2005","journal-title":"J Exp Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00688-08","article-title":"Expansion of human cytomegalovirus (HCMV) immediate-early 1-specific CD8+ T cells and control of HCMV replication after allogeneic stem cell transplantation","volume":"82","author":"Sacre","year":"2008","journal-title":"J virology."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-234906","article-title":"Allo-HLA reactivity of virus-specific memory T cells is common","volume":"115","author":"Amir","year":"2010","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-354787","article-title":"Allo-HLA reactive T cells inducing graft versus host disease are single peptide specific","volume":"118","author":"Amir","year":"2011","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1251593\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:46:04Z","timestamp":1698641164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1251593\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2023.1251593"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1251593","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"article-number":"1251593"}}